Vytrus Biotech (FRA:V5P) 3-Month Share Buyback Ratio: 0.00% (As of Dec. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:V5P Vytrus Biotech SA FRA:V5P
66 GF Score
Price €16.60
GF Value €6.99
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech 3-Month Share Buyback Ratio?

Vytrus Biotech FRA:V5P +2.15% 66 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus rates FRA:V5P with a GF Score™ of 66/100 and a GF Value™ of €6.99 (Significantly Overvalued). The stock has 2 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

FRA:V5P
66GF Score
Vytrus Biotech SA FRA:V5P
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Vytrus Biotech (FRA:V5P) has a 3-Month Share Buyback Ratio of 0.00 as of Dec. 2025. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Vytrus Biotech and its competitors.
Is Vytrus Biotech's 3-Month Share Buyback Ratio too high?
Vytrus Biotech's current 3-Month Share Buyback Ratio is 0.00. Overall, Vytrus Biotech has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's 3-Month Share Buyback Ratio compare to VRTX and REGN?
Vytrus Biotech's 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Vytrus Biotech and its competitors. Vytrus Biotech's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (FRA:V5P) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.99, compared to a current price of €16.60 — trading 137.5% above its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Vytrus Biotech's overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Vytrus Biotech (FRA:V5P), the current 3-Month Share Buyback Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vytrus Biotech (FRA:V5P) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €16.60 is trading 137.5% above its estimated GF Value™ of €6.99. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for FRA:V5P:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: €6.99 vs. price of €16.60 (137.5% above fair value)
  • GF Score™: 66/100 with 2 warning signs

No single metric tells the full story. See the FRA:V5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vytrus Biotech Business Description

Other Exchanges VYT:Spain
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
66GF Score

Get the complete analysis for FRA:V5P

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.60
Price
€6.99
GF Value